Cargando…
In vitro and Intracellular Antibacterial Activity of Sudapyridine (WX-081) Against Tuberculosis
BACKGROUND: Sudapyridine (WX-081) has exhibited equivalent efficacy than its counterpart parent drug bedaquiline (BDQ) but better safety profile against Mycobacterium tuberculosis (Mtb). Our study was aimed to evaluate in vitro activity of WX-081 against the clinical isolates of Mtb with different d...
Autores principales: | Xiao, Hua, Yu, Xia, Shang, Yuanyuan, Ren, Ruyan, Xue, Yi, Dong, Lingling, Zhao, Liping, Jiang, Guanglu, Huang, Hairong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840375/ https://www.ncbi.nlm.nih.gov/pubmed/36647451 http://dx.doi.org/10.2147/IDR.S390187 |
Ejemplares similares
-
In Vitro Activity of the Sudapyridine (WX-081) against Non-Tuberculous Mycobacteria Isolated in Beijing, China
por: Zhu, Rui, et al.
Publicado: (2022) -
Sudapyridine (WX-081), a Novel Compound against Mycobacterium tuberculosis
por: Yao, Rong, et al.
Publicado: (2022) -
Antibacterial activity of the novel compound Sudapyridine (WX-081) against Mycobacterium abscessus
por: Nie, Wenjuan, et al.
Publicado: (2023) -
Nosiheptide Harbors Potent In Vitro and Intracellular Inhbitory Activities against Mycobacterium tuberculosis
por: Yu, Xia, et al.
Publicado: (2022) -
Carbonyl Cyanide 3-Chlorophenylhydrazone (CCCP) Exhibits Direct Antibacterial Activity Against Mycobacterium abscessus
por: Chen, Suting, et al.
Publicado: (2021)